| 王爱军,孙 磊,李 明,李 俊,陆世琼,章福彬.参麦注射液联合西药对急性心肌梗死患者疗效及机制研究[J].,2021,(1):100-103 |
| 参麦注射液联合西药对急性心肌梗死患者疗效及机制研究 |
| Study on the Therapeutic Effect and Mechanism of Shenmai Injection Combined with Western Medicine in Patients with Acute Myocardial Infarction |
| 投稿时间：2020-03-28 修订日期：2020-04-24 |
| DOI：10.13241/j.cnki.pmb.2021.01.021 |
| 中文关键词: 参麦注射液 替格瑞洛 急性心肌梗死 |
| 英文关键词: Shenmai Injection Ticagrelor Acute Myocardial Infarction |
| 基金项目:国家自然科学基金项目（81671204） |
|
| 摘要点击次数: 949 |
| 全文下载次数: 525 |
| 中文摘要: |
| 摘要 目的：研究参麦注射液联合西药对急性心肌梗死患者的疗效及机制。方法：选择我院2016年3月～2019年12月收治的101例急性心肌梗死患者，根据随机数字表法分为对照组和观察组。对照组口服替格瑞洛治疗，观察组联用参麦注射液治疗，观察两组治疗的疗效及治疗前后血浆乳酸、脑钠肽（Brain natriuretic peptide，BNP）和血清降钙素原（Procalcitonin，PCT）、超敏C反应蛋白（Hypersensitive C-reactive protein，hs-CRP）水平及心功能指标变化。结果：观察组的有效率明显高于对照组(P<0.05)；两组治疗前的血浆乳酸、BNP和PCT、hs-CRP水平无明显差异(P>0.05)，治疗后，两组的上述指标明显降低(P<0.05)，且观察组低于对照组(P<0.05)；两组治疗前的左心室射血分数(Left ventricular ejection fraction，LVEF)、左心室舒张期末内径（End diastolic diameter of left ventricle，LVEDd）、CO和左心室收缩末期直径（leftventricular end systolic diameter，LVESd）无明显差异(P>0.05)，治疗后，两组的上述指标明显改善（P<0.05），且观察组优于对照组（P<0.05）；观察组的药物不良反应率为14.00 %（7/50），与对照组的11.76 %（6/51）相比无明显差异(P>0.05)。结论：参麦注射液联合替格瑞洛能减轻急性心肌梗死患者体内的炎症反应，改善心功能，可能与其机制有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect and mechanism of Shenmai injection combined with western medicine on patients with acute myocardial infarction. Methods: A total of 101 patients with acute myocardial infarction treated in our hospital from March 2016 to December 2019 were selected and divided into control group and observation group according to the random number table method. The control group was treated with oral ticagrelor, and the observation group was treated with Shenmai injection. The efficacy of the two groups and the plasma lactic acid, BNP, and serum PCT, hs-CRP levels and cardiac function indicators. Results: The effective rate of the observation group was significantly higher than that of the control group (P<0.05). There were no significant differences in plasma lactic acid, BNP, PCT, and hs-CRP levels between the two groups before treatment (P>0.05). After treatment, the above indicators in the two groups were significantly reduced (P<0.05), and the observation group was lower than the control group (P <0.05), there was no significant difference in LVEF, LVEDd, CO, and LVESd before treatment between the two groups (P>0.05). After treatment, the above indicators in the two groups improved significantly (P<0.05), and the observation group was better than the control group (P <0.05). The adverse drug reaction rate of the observation group was 14.00 % (7/50), and there was no significant difference between the observation group and the control group 11.76 % (6/51) (P>0.05). Conclusion: Shenmai injection combined with ticagrelor can reduce the inflammatory reaction in patients with acute myocardial infarction and improve the cardiac function, may be related to its mechanism. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
